Our Framework

Our Proprietary Analysis Framework

A structured, evidence-based approach to medical device due diligence — four assessment domains, proprietary scoring.

Schedule Discovery Call Learn More
Proprietary

Evaluated device outcomes

96%

Retrospective accuracy

4

Assessment domains

2-3 weeks

Typical assessment timeline

How It Works

From Submission to Strategic Insight

Your assessment moves through six integrated stages — each combining physician expertise with engineering rigor.

Step 1 of 6
Submit
Upload your materials
Clinical Review
Physician analysis
Technical Review
Engineering analysis
Pattern Match
proprietary database
Risk Scoring
Proprietary Vantage Score
Report Delivery
Actionable intelligence
01
Secure Document Upload
You provide company materials through our encrypted portal. We handle the rest. Typical uploads include pitch deck, regulatory filings, clinical data, financial projections, and competitive analysis.
Pitch deck & investor materials
FDA submissions & regulatory files
Clinical trial data & publications
Financial projections & cap table
Patent portfolio & IP filings
Manufacturing & quality docs
02
Physician Clinical Analysis
Our physician reviews from the clinical lens — the perspective VCs and consultants cannot replicate. This catches the adoption barriers that kill 75% of medical device startups.
Clinical adoption feasibility
Evidence & outcomes evaluation
Safety profile assessment
Competitive landscape analysis
03
Biomedical Engineering Review
Our BME assesses technical feasibility, manufacturing scalability, regulatory pathway, and IP strength — the engineering depth that separates real risk from surface-level DD.
Regulatory pathway assessment
Manufacturing & scalability review
IP strength evaluation
Design & quality analysis
04
Pattern Intelligence Engine
Your company's risk profile is cross-referenced against our proprietary database of documented medtech outcomes — spanning multiple device specialties — to surface patterns standard due diligence cannot detect.
Proprietary outcome database spanning multiple specialties
Failure pattern recognition across device categories
Success benchmarking against comparable exits
Cross-domain risk signal correlation
Historical precedent identification
96% historical accuracy
05
Proprietary Vantage Score
Each assessment produces a composite Vantage Score — a single, calibrated metric that synthesizes risk across all proprietary categories and four domains. The score distinguishes between risks that require immediate intervention and those manageable with the right roadmap.
Composite score across four assessment domains
Domain-level risk breakdown with justification
Terminal vs. remediable risk classification
Calibrated against documented outcomes
Stage-weighted scoring (seed through growth)
Prioritized remediation roadmap
06
Your Deliverable
A comprehensive report with executive summary, full proprietary scoring, risk analysis with historical precedents, remediation roadmap, and a 1-hour findings call with your team.
Executive Summary
Scoring Matrix
Remediation Plan
2-3 weeks

Four Assessment Domains, Proprietary Evaluation Categories

Our framework systematically evaluates medical devices across clinical, regulatory, engineering, and commercial dimensions — the areas where most device failures originate. Each domain contains proprietary risk categories refined through analysis of documented device outcomes.

Clinical

Multiple categories assessing clinical need, evidence strength, adoption barriers, and physician workflow integration — the factors that kill 75% of medical device startups.

Physician-led review

Regulatory

Multiple categories covering pathway risk, reimbursement viability, quality system maturity, and post-market readiness — where regulatory missteps create 12-18 month delays.

Pathway & compliance

Engineering

Multiple categories evaluating design maturity, manufacturing scalability, supply chain resilience, and IP defensibility — the silent portfolio killers.

Engineering-led review

Commercial

Multiple categories stress-testing market assumptions, unit economics, workflow integration, team execution capacity, and exit value — under real-world conditions, not pitch deck projections.

Market & exit analysis

The specific categories, evaluation criteria, and scoring weights are proprietary — refined through analysis of documented device outcomes and tailored by stage, device class, and intended market.

We share the full framework under NDA during discovery calls so you can evaluate our approach before engaging. Request a methodology briefing →

What Sets Us Apart

Beyond Standard Due Diligence

Proprietary Scoring

Every assessment domain receives a proprietary Vantage Score with detailed justification. Our scoring system distinguishes between risks that require immediate intervention and those that are manageable with appropriate resources and timeline. The composite Vantage Score gives you a single, calibrated number backed by domain-level detail.

Terminal Risk Identification

Not all risks are equal. Our framework distinguishes between risks that can be mitigated through execution and those that represent fundamental structural barriers. This distinction is one of the most decision-relevant outputs of our analysis.

Our Proprietary Analysis Framework

Our proprietary analysis combines physician and biomedical engineering domain expertise with a database of documented medical device outcomes. For each assessment, we compare your device against similar technologies in our database — both successes and failures — to contextualize risk and identify patterns that predict outcomes.

Ready to Get a Vantage Assessment?

In 2-3 weeks, you'll have a comprehensive risk report and a clear roadmap for your next steps.

Schedule Discovery Call Free 20-Min Call

Not sure if you need an assessment? In a free 20-minute call, we'll identify the 3 biggest risks in your device category.

Based on retrospective analysis of documented device outcomes in our proprietary database. Accuracy represents the proportion of devices correctly classified into risk categories compared to subsequent clinical and commercial outcomes.

Schedule a Call